JCR Pharmaceuticals
Biosimilar developer, Japan. 3 development products across 3 molecules: agalsidase beta, darbepoetin alfa, epoetin alfa and zeta.
First approval in the Atlas: Jan 2010, Epoetin Alfa BS [JCR], epoetin alfa and zeta (PMDA)
FDAproducts approved0
EMAproducts approved0
PMDAproducts approved3
HCproducts approved0
CDSCOproducts approved0
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Agalsidase beta | Agalsidase Beta BS JCR | · | · | Sep 2018 | · | · | · |
| Darbepoetin alfa | Darbepoetin Alfa BS JCR | · | · | Sep 2019 | · | · | · |
| Epoetin alfa and zeta | Epoetin Alfa BS JCR | · | · | Jan 2010 | · | · | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- PMDAJan 2010Epoetin Alfa BS [JCR], epoetin alfa and zeta
- PMDASep 2018Agalsidase Beta BS [JCR], agalsidase beta
- PMDASep 2019Darbepoetin Alfa BS [JCR], darbepoetin alfa
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.